Can I read Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms on EtoBox?

Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms by Marco Benati; Martina Montagnana; Elisa Danese; Giovanna De Matteis; Dino Veneri; Elisa Paviati; Gian Cesare Guidi is a Medicine article available to read on EtoBox.

What is Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms about?

Background: Myeloproliferative neoplasms (MPNs) are clonal myeloid disorders characterized by the overproduction of mature blood cells. The pathogenetic hallmark of MPNs is the dysregulation of JAK-STAT signaling, usually associated with the JAK2 V617F mutation. Multiple additional genetic and epigenetic alterations that constitutively activate the JAK-STAT signaling pathway have been described, including the modulation of the microRNAs (miRs) expression levels. The aims of our study were to investigate JAK2 V617F mutation allele burden and miR-143 expression levels in MPNs patients and to investigate the correlation between these genetic signatures and hematological parameters. Methods: In total 78 patients with a clinical diagnosis of polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IM), made according to the WHO 2008 criteria, were included in the study. Twenty healthy subjects were checked as controls. Quantification of JAK2 V617F mutation and miR-143 expression levels were determined by real-time quantitative polymerase chain reaction. ## Results: The miR-143 expression in MPNs patients was 2.97fold higher than in controls. JAK2 V617F mutati

Who reads Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms?

Author

Marco Benati; Martina Montagnana; Elisa Danese; Giovanna De Matteis; Dino Veneri; Elisa Paviati; Gian Cesare Guidi

Publisher

Walter de Gruyter GmbH

Published

2015

Language

EN

Field

Medicine (Health Sciences)